Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study

Arthritis and Rheumatology

Volumn 68, Issue 11, 2016, Pages 2671-2679

  Sepriano, A ^a,b   Ramiro, S ^a,b   van der Heijde, D ^b   Avila Ribeiro P ^c   Fonseca, R ^d   Borges, J ^e   Teixeira, L ^f   Carvalho, P D ^g   Cerqueira, M ^h   Neves, J ^h   Meirinhos, T ⁱ   Barcelos, A ⁱ   Sequeira, G ^j   Salvador, M J ^g   Canas da Silva, J ^f   Santos, H ^e   Bernardes, M ^d   Vieira Sousa, E ^k   Canhao H ^k   Branco, J C ^a,l   Pimentel Santos, F ^a,l   Landewe R ^m,n   more..

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Lisbon Academic Medical Centre   (Portugal)

^d Universidade do Porto   (Portugal)

^e INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

^f HOSPITAL GARCIA DE ORTA   (Portugal)

^g CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^h Unidade Local de Saude do Alto Minho   (Portugal)

ⁱ Hospital Infante D Pedro EPE   (Portugal)

^j HOSPITAL DE FARO   (Portugal)

^k Lisbon Academic Medical Center and Instituto de Medicina Molecular   (Portugal)

^l HOSPITAL EGAS MONIZ   (Portugal)

^m UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁿ Zuyderland Medical Centre   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ALLERGIC REACTION; ARTICLE; BREAST CANCER; CARCINOID; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; PROSTATE CANCER; PSORIASIS; SIDE EFFECT; SPONDYLARTHRITIS; TUBERCULOSIS; COMBINATION DRUG THERAPY; DEPRESCRIPTION; ERYTHROCYTE SEDIMENTATION RATE; IMMUNOLOGY; MIDDLE AGED; PAIN MEASUREMENT; PATHOPHYSIOLOGY; SPONDYLARTHROPATHIES; TIME FACTOR;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; DEPRESCRIPTIONS; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; SPONDYLARTHRITIS; SPONDYLARTHROPATHIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84992670233     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39772     Document Type: Article

References (30)

1. Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2015;74:1241–8.
2. Sieper J. Developments in therapies for spondyloarthritis. Nat Rev Rheumatol 2012;8:280–7.
3. Davis JC Jr, van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005;32:1751–4.
4. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665–70.
5. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801–8.
6. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619–32.
7. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. Part II. Second line drugs and prednisone. J Rheumatol 1992;19:1885–94.
8. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO Registry. Ann Rheum Dis 2010;69:2002–8.
9. Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234–40.
10. Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010;62:1362–9.
11. Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandstrom T, Askling J, Jacobsson LT, et al. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 2015;74:970–8.
12. Landewe RB. Conventional DMARDs in axial spondyloarthritis: wishful–rather than rational–thinking! Ann Rheum Dis 2015;74:951–3.
13. Landewe RB. Methotrexate saves lives: a pearl of observational research. Arthritis Rheum 2013;65:307–9.
14. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424.
15. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-α blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011;13:R94.
16. Busquets N, Tomero E, Descalzo MA, Ponce A, Ortiz-Santamaria V, Suris X, et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 Registry. Rheumatology (Oxford) 2011;50:1999–2004.
17. Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S, et al. C-reactive protein predicts tumor necrosis factor-α blocker retention rate in axial ankylosing spondylitis. J Rheumatol 2007;34:2078–81.
18. Gulfe A, Kapetanovic MC, Kristensen LE. Efficacy and drug survival of anti-tumour necrosis factor-α therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden. Scand J Rheumatol 2014;43:493–7.
19. Carmona L, Gomez-Reino JJ, BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
20. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433–8.
21. Canhao H, Faustino A, Martins F, Fonseca JE. Reuma.pt: the Rheumatic Diseases Portuguese Register. Acta Reumatol Port 2011;36:45–56.
22. Van der Meulen JH, Jacob M, Copley L. Assessing the quality of the data in a transplant registry: the European Liver Transplant Registry. Transplantation 2003;75:2164–7.
23. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24.
24. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
25. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.
26. Sieper J, Rudwaleit M, Braun J. Adalimumab for the treatment of ankylosing spondylitis. Expert Opin Pharmacother 2007;8:831–8.
27. Hertz-Picciotto I, Rockhill B. Validity and efficiency of approximation methods for tied survival times in Cox regression. Biometrics 1997;53:1151–6.
28. Schwartz S, Campbell UB, Gatto NM, Gordon K. Toward a clarification of the taxonomy of “bias” in epidemiology textbooks. Epidemiology 2015;26:216–22.
29. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002;359:248–52.
30. Maksymowych WP. Biomarkers in axial spondyloarthritis. Curr Opin Rheumatol 2015;27:343–8.